Lily Van1,2, Nancy J Butcher1,3, Gregory Costain1,2, Lucas Ogura1, Eva W C Chow1,4, Anne S Bassett1,3,4,5,6,7,8. 1. Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. Undergraduate Medical Education, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3. Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 5. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 6. Department of Psychiatry, Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada. 7. Division of Cardiology, Department of Medicine, University Health Network, Toronto, Ontario, Canada. 8. The Dalglish Family Hearts and Minds Clinic for Adults with 22q11.2 Deletion Syndrome, University Health Network, Toronto, Ontario, Canada.
Abstract
PURPOSE: Schizophrenia occurs in 20-25% of adults with 22q11.2 deletion syndrome (22q11.2DS). General population studies of schizophrenia report associations with perinatal complications, although effect sizes are generally low. We aimed to determine whether such factors are associated with expression of schizophrenia in individuals with 22q11.2DS. METHODS: We investigated the relationship of small for gestational age (SGA) birth weight (<3rd percentile for sex and gestational age) and prematurity (<37 weeks gestation) to expression of schizophrenia in a well-characterized cohort of 123 adults with 22q11.2DS. Outcome measures included adjusted odds ratios and positive and negative predictive values (PPV and NPV) for schizophrenia. RESULTS: SGA birth weight (OR = 3.52, 95% CI = 1.34-9.22) and prematurity (OR = 5.38, 95% CI = 1.63-17.75), but not maternal factors, were significant risk factors for schizophrenia in 22q11.2DS. Being born SGA or premature resulted in a PPV of 46% for schizophrenia; NPV in the absence of both features was 83%. Post hoc analyses suggested these perinatal complications were also associated with factors indicative of increased severity of schizophrenia. CONCLUSION: In 22q11.2DS, fetal growth and gestation may have a clinically significant impact on future risk for schizophrenia. These data advance our understanding of determinants of disease-specific expression in 22q11.2DS, with implications for other genomic disorders.Genet Med 18 4, 350-355.
PURPOSE: Schizophrenia occurs in 20-25% of adults with 22q11.2 deletion syndrome (22q11.2DS). General population studies of schizophrenia report associations with perinatal complications, although effect sizes are generally low. We aimed to determine whether such factors are associated with expression of schizophrenia in individuals with 22q11.2DS. METHODS: We investigated the relationship of small for gestational age (SGA) birth weight (<3rd percentile for sex and gestational age) and prematurity (<37 weeks gestation) to expression of schizophrenia in a well-characterized cohort of 123 adults with 22q11.2DS. Outcome measures included adjusted odds ratios and positive and negative predictive values (PPV and NPV) for schizophrenia. RESULTS: SGA birth weight (OR = 3.52, 95% CI = 1.34-9.22) and prematurity (OR = 5.38, 95% CI = 1.63-17.75), but not maternal factors, were significant risk factors for schizophrenia in 22q11.2DS. Being born SGA or premature resulted in a PPV of 46% for schizophrenia; NPV in the absence of both features was 83%. Post hoc analyses suggested these perinatal complications were also associated with factors indicative of increased severity of schizophrenia. CONCLUSION: In 22q11.2DS, fetal growth and gestation may have a clinically significant impact on future risk for schizophrenia. These data advance our understanding of determinants of disease-specific expression in 22q11.2DS, with implications for other genomic disorders.Genet Med 18 4, 350-355.
Authors: Chiara Nosarti; Abraham Reichenberg; Robin M Murray; Sven Cnattingius; Mats P Lambe; Li Yin; James MacCabe; Larry Rifkin; Christina M Hultman Journal: Arch Gen Psychiatry Date: 2012-06
Authors: Nancy J Butcher; Wai Lun Alan Fung; Laura Fitzpatrick; Alina Guna; Danielle M Andrade; Anthony E Lang; Eva W C Chow; Anne S Bassett Journal: Br J Psychiatry Date: 2015-03-05 Impact factor: 9.319
Authors: R Reynaud; J Derain-Court; D Braunstein; M Veyrat; J Gaudart; F Giuliano; N Philip Journal: Horm Res Paediatr Date: 2011-08-05 Impact factor: 2.852
Authors: David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter Journal: Am J Hum Genet Date: 2010-05-14 Impact factor: 11.025
Authors: Anne-Karen von Beckerath; Martina Kollmann; Christa Rotky-Fast; Eva Karpf; Uwe Lang; Philipp Klaritsch Journal: Am J Obstet Gynecol Date: 2012-11-15 Impact factor: 8.661
Authors: Donna M McDonald-McGinn; Kathleen E Sullivan; Bruno Marino; Nicole Philip; Ann Swillen; Jacob A S Vorstman; Elaine H Zackai; Beverly S Emanuel; Joris R Vermeesch; Bernice E Morrow; Peter J Scambler; Anne S Bassett Journal: Nat Rev Dis Primers Date: 2015-11-19 Impact factor: 52.329
Authors: Sarah L Voll; Erik Boot; Nancy J Butcher; Samantha Cooper; Tracy Heung; Eva W C Chow; Candice K Silversides; Anne S Bassett Journal: Genet Med Date: 2016-08-18 Impact factor: 8.822
Authors: Nancy J Butcher; Daniele Merico; Mehdi Zarrei; Lucas Ogura; Christian R Marshall; Eva W C Chow; Anthony E Lang; Stephen W Scherer; Anne S Bassett Journal: PLoS One Date: 2017-04-21 Impact factor: 3.240